Do analysts prefer ALMS or RDY?

Alumis presently has a consensus target price of $40.30, suggesting a potential upside of 51.28%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media refer more to ALMS or RDY?

In the previous week, Alumis and Alumis both had 2 articles in the media. Alumis' average media sentiment score of 0.94 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ALMS or AXSM?

Axsome Therapeutics has higher revenue and earnings than Alumis. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 141.22 -$243.32M -$1.98 N/A Axsome Therapeutics $638.50M 19.40 -$183.17M -$3.73 N/A

Is ALMS or AXSM more profitable?

Axsome Therapeutics has a net margin of -26.59% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Axsome Therapeutics -26.59% -267.16% -28.53%

Does the media refer more to ALMS or AXSM?

In the previous week, Axsome Therapeutics had 4 more articles in the media than Alumis. MarketBeat recorded 6 mentions for Axsome Therapeutics and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Axsome Therapeutics' score of 0.77 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer ELAN or ALMS?

In the previous week, Elanco Animal Health had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Elanco Animal Health and 2 mentions for Alumis. Elanco Animal Health's average media sentiment score of 1.13 beat Alumis' score of 0.94 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or ALMS?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Alumis. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 2 mentions for Alumis. Arrowhead Pharmaceuticals' average media sentiment score of 0.99 beat Alumis' score of 0.94 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMMT or ALMS more profitable?

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Alumis -2,825.70% -88.79% -70.72%

Does the media prefer SMMT or ALMS?

In the previous week, Summit Therapeutics and Summit Therapeutics both had 2 articles in the media. Summit Therapeutics' average media sentiment score of 1.81 beat Alumis' score of 0.94 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alumis (ALMS) Competitors

$26.64 -1.50 (-5.33%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$26.64 +0.00 (+0.02%)

As of 07/1/2026 07:44 PM Eastern

Compare

ALMS vs. RDY, AXSM, ELAN, ARWR, and SMMT

Should you buy Alumis stock or one of its competitors? MarketBeat compares Alumis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alumis include Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Alumis compare to Dr. Reddy's Laboratories?

Alumis (NASDAQ:ALMS) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Alumis has a beta of -0.74, suggesting that its stock price is 174% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

In the previous week, Alumis and Alumis both had 2 articles in the media. Alumis' average media sentiment score of 0.94 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Alumis' net margin of -2,825.70%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alumis presently has a consensus target price of $40.30, suggesting a potential upside of 51.28%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A
Dr. Reddy's Laboratories	$3.58B	3.27	$456M	$0.58	24.21

Summary

Dr. Reddy's Laboratories beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Axsome Therapeutics?

Alumis (NASDAQ:ALMS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Axsome Therapeutics has a net margin of -26.59% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Alumis presently has a consensus price target of $40.30, indicating a potential upside of 51.28%. Axsome Therapeutics has a consensus price target of $258.95, indicating a potential upside of 7.60%. Given Alumis' higher possible upside, equities research analysts plainly believe Alumis is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Alumis has a beta of -0.74, suggesting that its share price is 174% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 4 more articles in the media than Alumis. MarketBeat recorded 6 mentions for Axsome Therapeutics and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Axsome Therapeutics' score of 0.77 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Axsome Therapeutics has higher revenue and earnings than Alumis. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A
Axsome Therapeutics	$638.50M	19.40	-$183.17M	-$3.73	N/A

81.5% of Axsome Therapeutics shares are owned by institutional investors. 33.7% of Alumis shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Axsome Therapeutics beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

In the previous week, Elanco Animal Health had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Elanco Animal Health and 2 mentions for Alumis. Elanco Animal Health's average media sentiment score of 1.13 beat Alumis' score of 0.94 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has a net margin of -4.95% compared to Alumis' net margin of -2,825.70%. Elanco Animal Health's return on equity of 7.42% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Alumis	-2,825.70%	-88.79%	-70.72%

Elanco Animal Health currently has a consensus target price of $28.55, indicating a potential upside of 18.57%. Alumis has a consensus target price of $40.30, indicating a potential upside of 51.28%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Elanco Animal Health has higher revenue and earnings than Alumis. Elanco Animal Health is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.55	-$232M	-$0.50	N/A
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Alumis has a beta of -0.74, meaning that its share price is 174% less volatile than the broader market.

Summary

Elanco Animal Health beats Alumis on 10 of the 15 factors compared between the two stocks.

How does Alumis compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Alumis. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 2 mentions for Alumis. Arrowhead Pharmaceuticals' average media sentiment score of 0.99 beat Alumis' score of 0.94 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Alumis' net margin of -2,825.70%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Alumis	-2,825.70%	-88.79%	-70.72%

Arrowhead Pharmaceuticals has higher revenue and earnings than Alumis. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	13.66	-$1.63M	-$2.15	N/A
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A

Arrowhead Pharmaceuticals currently has a consensus price target of $87.27, indicating a potential upside of 8.49%. Alumis has a consensus price target of $40.30, indicating a potential upside of 51.28%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Arrowhead Pharmaceuticals has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Alumis has a beta of -0.74, meaning that its stock price is 174% less volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Alumis	-2,825.70%	-88.79%	-70.72%

Alumis has higher revenue and earnings than Summit Therapeutics. Alumis is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A

In the previous week, Summit Therapeutics and Summit Therapeutics both had 2 articles in the media. Summit Therapeutics' average media sentiment score of 1.81 beat Alumis' score of 0.94 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market. Comparatively, Alumis has a beta of -0.74, suggesting that its stock price is 174% less volatile than the broader market.

Summit Therapeutics presently has a consensus price target of $26.97, suggesting a potential upside of 87.57%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 51.28%. Given Summit Therapeutics' higher possible upside, equities research analysts plainly believe Summit Therapeutics is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Summit Therapeutics and Alumis tied by winning 7 of the 14 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.59B	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.15%
P/E Ratio	-13.45	21.28	27.41	25.26
Price / Sales	141.22	324.37	533.25	101.17
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	9.25	8.71	10.96	6.62
Net Income	-$243.32M	$23.87M	$3.57B	$336.83M
7 Day Performance	6.43%	4.34%	2.89%	3.19%
1 Month Performance	32.93%	6.62%	3.70%	0.86%
1 Year Performance	712.20%	61.64%	34.39%	27.51%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.1432 of 5 stars	$26.64 -5.3%	$40.30 +51.3%	+782.1%	$3.59B	$24.05M	N/A	N/A
RDY Dr. Reddy's Laboratories	1.7035 of 5 stars	$15.39 +0.9%	N/A	-6.0%	$12.73B	$3.58B	26.53	27,527
AXSM Axsome Therapeutics	2.0901 of 5 stars	$242.15 +2.0%	$258.95 +6.9%	+133.7%	$12.21B	$638.50M	N/A	380	Positive News Insider Trade Gap Up High Trading Volume
ELAN Elanco Animal Health	3.9158 of 5 stars	$24.56 +0.8%	$28.55 +16.2%	+66.7%	$12.17B	$4.72B	N/A	9,400	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2902 of 5 stars	$78.89 -0.5%	$86.36 +9.5%	+399.9%	$11.17B	$829.45M	N/A	400	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. RDY, AXSM, ELAN, ARWR, and SMMT

How does Alumis compare to Dr. Reddy's Laboratories?

Summary

How does Alumis compare to Axsome Therapeutics?

Summary

How does Alumis compare to Elanco Animal Health?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Summary

How does Alumis compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. RDY, AXSM, ELAN, ARWR, and SMMT

How does Alumis compare to Dr. Reddy's Laboratories?

Which has more volatility & risk, ALMS or RDY?

Does the media refer more to ALMS or RDY?

Is ALMS or RDY more profitable?

Do institutionals and insiders believe in ALMS or RDY?

Do analysts prefer ALMS or RDY?

Which has preferable valuation & earnings, ALMS or RDY?

Summary

How does Alumis compare to Axsome Therapeutics?

Is ALMS or AXSM more profitable?

Do analysts rate ALMS or AXSM?

Which has more volatility & risk, ALMS or AXSM?

Does the media refer more to ALMS or AXSM?

Which has higher earnings and valuation, ALMS or AXSM?

Do institutionals and insiders have more ownership in ALMS or AXSM?

Summary

How does Alumis compare to Elanco Animal Health?

Does the media prefer ELAN or ALMS?

Is ELAN or ALMS more profitable?

Do analysts rate ELAN or ALMS?

Which has higher earnings & valuation, ELAN or ALMS?

Do insiders and institutionals believe in ELAN or ALMS?

Which has more risk and volatility, ELAN or ALMS?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Does the media favor ARWR or ALMS?

Do institutionals and insiders believe in ARWR or ALMS?

Is ARWR or ALMS more profitable?

Which has stronger valuation and earnings, ARWR or ALMS?

Do analysts rate ARWR or ALMS?

Which has more risk & volatility, ARWR or ALMS?

Summary

How does Alumis compare to Summit Therapeutics?

Is SMMT or ALMS more profitable?

Which has better earnings & valuation, SMMT or ALMS?

Does the media prefer SMMT or ALMS?

Which has more volatility and risk, SMMT or ALMS?

Do analysts recommend SMMT or ALMS?

Do institutionals and insiders hold more shares of SMMT or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools